Our data revealed that neither tumor-infiltrating CD8 TRM nor its CD39+ or PD-L1+ subset provided additional advantages over total tumor-infiltrating CD8 T cells in predicting the efficacy of ICB-based immunotherapy in patients with advanced HCC. This evidence concerns the gene CD8A and neoplasm.